8259

0

MADHAVBAUG

img img img img
No Data Available

VAIDYA SANE AYUR LAB LTD Share Price Update

As of the latest trading session, VAIDYA SANE AYUR LAB LTD is trading at ₹199.95, up by ₹6.55 or 3.38% from its previous close. The stock has moved between ₹191.25 and ₹200.00 today. Over the past year, the stock has delivered a return of 40.65%. In the last month, it has returned 0.49%.

VAIDYA SANE AYUR LAB LTD performance

Today’s low Today’s high
₹ 191.25 ₹ 200.00
₹ 196.00
52 week low 52 week high
₹ 137.50 ₹ 335.00
₹ 196.00
Open Price ₹ 195.00
Prev. Close ₹ 193.40
Volume (Shares) 7600.00
Total traded value ₹ 14.89
Upper Circuit ₹ 232.05
Lower Circuit ₹ 154.75
info

Investment Returns

Over 1 Month 0.49% Over 3 Months -7.70% Over 6 Months -28.66% Over 1 Year 40.65%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

VAIDYA SANE AYUR LAB LTD fundamentals


  • Market cap (Cr) 206.10
  • P/E Ratio (TTM) 41.24
  • Beta 0.86
  • Book Value / share 76.46
  • Return on equity 10.04%
  • EPS (TTM) 4.69
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 0.00
info icon alternate text
  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) [-]
info icon alternate text

VAIDYA SANE AYUR LAB LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 99.62
Operating Expense 95.73
Net Profit 4.93
Net Profit Margin (%) 4.94
Earnings Per Share (EPS) 4.69
EBITDA 12.51
Effective Tax Rate (%) 18.88
Particulars MAR 2025 (Values in Cr)
Revenue 87.11
Operating Expense 80.79
Net Profit 4.90
Net Profit Margin (%) 5.62
Earnings Per Share (EPS) 4.66
EBITDA 11.46
Effective Tax Rate (%) 28.67
Particulars MAR 2024 (Values in Cr)
Revenue 97.33
Operating Expense 97.44
Net Profit 1.05
Net Profit Margin (%) 1.07
Earnings Per Share (EPS) 0.99
EBITDA 4.72
Effective Tax Rate (%) 28.27
Particulars MAR 2023 (Values in Cr)
Revenue 99.03
Operating Expense 93.48
Net Profit 5.19
Net Profit Margin (%) 5.24
Earnings Per Share (EPS) 4.94
EBITDA 9.70
Effective Tax Rate (%) 24.89
Particulars MAR 2022 (Values in Cr)
Revenue 74.71
Operating Expense 70.30
Net Profit 3.47
Net Profit Margin (%) 4.64
Earnings Per Share (EPS) 8.00
EBITDA 7.24
Effective Tax Rate (%) 26.94
Particulars MAR 2025 (Values in Cr)
Book Value / Share 59.44
ROE % 13.58
ROCE % 17.67
Total Debt to Total Equity 0.03
EBITDA Margin 17.09
Particulars MAR 2024 (Values in Cr)
Book Value / Share 40.10
ROE % 3.19
ROCE % 5.42
Total Debt to Total Equity 0.02
EBITDA Margin 5.95
Particulars MAR 2023 (Values in Cr)
Book Value / Share 38.48
ROE % 11.94
ROCE % 17.30
Total Debt to Total Equity 0.00
EBITDA Margin 9.97
Particulars MAR 2025 (Values in Cr)
Book Value / Share 56.78
ROE % 10.04
ROCE % 13.28
Total Debt to Total Equity 0.03
EBITDA Margin 13.66
Particulars MAR 2024 (Values in Cr)
Book Value / Share 39.56
ROE % 1.65
ROCE % 2.97
Total Debt to Total Equity 0.02
EBITDA Margin 4.65
Particulars MAR 2023 (Values in Cr)
Book Value / Share 38.82
ROE % 13.54
ROCE % 19.16
Total Debt to Total Equity 0.02
EBITDA Margin 10.46
Particulars MAR 2022 (Values in Cr)
Book Value / Share 34.13
ROE % 15.20
ROCE % 20.93
Total Debt to Total Equity 0.05
EBITDA Margin 10.25
Particulars MAR 2021 (Values in Cr)
Book Value / Share 2170.44
ROE % 10.34
ROCE % 14.76
Total Debt to Total Equity 0.39
EBITDA Margin 8.74
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2.36
Total Assets 76.70
Total Liabilities 76.70
Total Equity 62.53
Share Outstanding 1
Price to Book Ratio 1.65
Return on Assets (%) 9.32
Return on Capital (%) 11.18
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 2.37
Total Assets 69.71
Total Liabilities 69.71
Total Equity 55.60
Share Outstanding 1
Price to Book Ratio 4.40
Return on Assets (%) 2.84
Return on Capital (%) 3.46
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1.76
Total Assets 54.88
Total Liabilities 54.88
Total Equity 40.45
Share Outstanding 1
Price to Book Ratio 6.05
Return on Assets (%) 8.80
Return on Capital (%) 11.91
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 2.32
Total Assets 73.82
Total Liabilities 73.82
Total Equity 59.70
Share Outstanding 1
Price to Book Ratio 1.65
Return on Assets (%) 6.63
Return on Capital (%) 8.01
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 2.18
Total Assets 70.73
Total Liabilities 70.73
Total Equity 55.02
Share Outstanding 1
Price to Book Ratio 4.40
Return on Assets (%) 1.47
Return on Capital (%) 1.84
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1.75
Total Assets 55.27
Total Liabilities 55.27
Total Equity 40.80
Share Outstanding 1
Price to Book Ratio 6.05
Return on Assets (%) 9.38
Return on Capital (%) 12.68
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 2.56
Total Assets 50.00
Total Liabilities 50.00
Total Equity 35.88
Share Outstanding 1
Price to Book Ratio 5.71
Return on Assets (%) 6.93
Return on Capital (%) 9.39
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.90
Total Assets 25.80
Total Liabilities 25.80
Total Equity 9.76
Share Outstanding 0
Price to Book Ratio 0.00
Return on Assets (%) 1.51
Return on Capital (%) 3.64
Particulars MAR 2025 (Values in Cr)
Net Income 9.89
Cash from Operations 12.47
Cash from Investing -10.07
Cash from Financing -0.53
Net change in Cash -0.01
Free Cash Flow 20.92
Particulars MAR 2024 (Values in Cr)
Net Income 2.86
Cash from Operations -0.38
Cash from Investing -12.99
Cash from Financing 14.86
Net change in Cash 0.60
Free Cash Flow 10.76
Particulars MAR 2023 (Values in Cr)
Net Income 6.43
Cash from Operations 2.68
Cash from Investing 0.51
Cash from Financing -1.37
Net change in Cash -0.79
Free Cash Flow 9.66
Particulars MAR 2025 (Values in Cr)
Net Income 6.86
Cash from Operations 8.60
Cash from Investing -6.90
Cash from Financing -0.54
Net change in Cash 0.13
Free Cash Flow 15.87
Particulars MAR 2024 (Values in Cr)
Net Income 1.45
Cash from Operations 4.20
Cash from Investing -17.42
Cash from Financing 14.46
Net change in Cash 0.43
Free Cash Flow 9.29
Particulars MAR 2023 (Values in Cr)
Net Income 6.91
Cash from Operations 2.19
Cash from Investing 0.99
Cash from Financing -1.37
Net change in Cash -0.80
Free Cash Flow 9.17
Particulars MAR 2022 (Values in Cr)
Net Income 4.74
Cash from Operations -12.12
Cash from Investing -7.52
Cash from Financing 22.49
Net change in Cash 1.65
Free Cash Flow -8.95
Particulars MAR 2021 (Values in Cr)
Net Income 1.60
Cash from Operations 6.38
Cash from Investing -0.66
Cash from Financing -5.25
Net change in Cash -0.15
Free Cash Flow 7.29
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
APOLLO HOSPITALS ENTER. L 8304.10 61.04 12.60 119400.22 6680.00 8386.00
FORTIS MALAR HOSPITALS LIMITED 53.54 24.23 2.92 100.34 40.75 78.60
SHREE PACETRONIX LTD. 131.95 19.90 2.91 49.48 66.10 283.15
TRANSGENE BIOTEK LTD. 3.17 0.00 2.60 24.02 1.83 5.26
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
APOLLO HOSPITALS ENTER. L 8304.10 79.53 11.98 119400.22 6680.00 8386.00
[-] 0.0 0.0 0.0 0.0 0.0 0.0
CHENNAI MEENAKSHI MULTISPECIAL 38.50 0.00 -11.18 28.76 30.30 57.48
KOVAI MEDICAL CENTER & HO 5403.50 25.07 4.96 5911.43 5010.00 6725.00

VAIDYA SANE AYUR LAB LTD shareholding pattern

Holding
33.66%
66.33%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

VAIDYA SANE AYUR LAB LTD Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
196.00 1.34 redarrow
red-green-graph indicator
16 Bearish
0 Bullish
  • 5 Days 205.30
  • 26 Days 224.80
  • 10 Days 219.50
  • 50 Days 224.20
  • 12 Days 222.20
  • 100 Days 229.00
  • 20 Days 225.20
  • 200 Days 224.90
192.82 PIVOT
First Support 190.63 First Resistance 195.58 Second Support 187.87 Second Resistance 197.77 Third Support 185.68 Third Resistance 200.53
RSI 39.02 ADX 34.59 MACD -2.59 Williams % R -90.96 Commodity Channel Index (CCI) -123.16
Date 2026-05-21 Week 19400.00 Same Day 10800.00 Month 20982.00
1 Year 0.86 3 Year 0.57
Over 1 Month
0.49% down
Over 1 Year
40.65% down
Over 3 Months
-7.70% down
Over 3 Years
-7.03% down
Over 6 Months
-28.66% down
Over 5 Years
12.90% down

VAIDYA SANE AYUR LAB LTD Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
05 Sep 2023 0.25 Final 06 Sep 2023 Equity shares
18 Nov 2022 0.25 Interim 18 Nov 2022 Equity shares

Top Gainers

Top Losers

VAIDYA SANE AYUR LAB LTD Share Price

Vaidya Sane Ayurved Laboratories Limited was originally incorporated as a Private Limited Company pursuant to a Certificate of Incorporation issued by the Registrar of Companies, Pune dated April 6, 1999 with the name Vaidya Sane Ayurved Laboratories Private Limited'. Subsequently, Company was converted into to a Public Limited Company and the name of Company was changed to Vaidya Sane Ayurved Laboratories Limited'. A fresh Certificate of Incorporation upon conversion was issued on November 25, 2021 by the Registrar of Companies, Pune.

The Company is a unique medical service institution to treat chronic ailments like cardiac disease, diabetes, hypertension and obesity with the distinctive outlook of amalgamating technology with traditional healing of Ayurveda. Its approach to treatment using non-invasive, multidisciplinary and innovative therapies has helped the Company for treating the chronic ailments.

The Company is primarily engaged in research and development in ayurvedic medicines and the sale of ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurvedic medical professional services across its various clinics including panchkarma and other ayurvedic treatments through running of ayurvedic Hospital.

The Company is a health care provider primarily in the India's chronic care ecosystem. It operate 302 clinics across Maharashtra, Madhya Pradesh, Gujarat, Uttar Pradesh, Kerala, Goa, Chhattisgarh and Karnataka. Out of these 49 are company owned, 57 are OPD's and 196 are franchise clinics. The Company operate two cardiac prevention and rehabilitation hospitals in Khopoli and Kondhali respectively. Currently, the Company has a network including 302 Clinics and 2 Fully equipped Hospital.

The Company has entered into MOU dated April 1, 2019 with Vaidya Sane's Ayurvedic Education And Agricultural Research Trust for the entire management, medical services and treatments being carried out at Khopoli Hospital. The Company use clinic based health care delivery model along with tele-medicine to ensure easy accessibility to patients. Apart from treatments, as a means of raising awareness about disease and its associated complications, the Company conduct a number of workshops, support events etc. with a singular objective of helping patients manage their chronic non-communicable conditions more effectively as well.

In 2006, First Cardiac Prevention and Rehabilitation Hospital was set up at Khopoli and inaugurated opening of first Madhavbaug Clinic at Dombivili, Maharashtra.

In 2009, the Company established in house research and development team at Thane.

In 2012, the Company established the First Cardiac Prevention and Rehabilitation Hospital at Nagpur.

In 2013, the Company inaugurated opening of 100th Madhavbaug Clinic at Kankavli, in Ratnagiri.

In 2014, the Company launched Arogyam Hriday Sampada with a Mission to create awareness of heart disease.

In 2015, the Company launched therapies for risk factors such as diabetes, obesity and hypertension at Madhavbaug Clinics.

In 2016, the Company launched a research based disease wise diet kits at Madhavbaug Clinics for aiding healthcare programmes and established Madhavbaug Institute of Preventive Cardiology with MUHS. These kits aid in the recovery and rehabilitation of its patients.

In 2017, Madhavbaug Clinics received Frost and Sullivan's 2017 India Best Practices Award and the Company's randomized controlled trial by Madhavbaug was published in Indian Heart Journal, Official publication of Cardiological Society of India.

In 2018, Madhavbaug Clinics ventured into India Book of Records for conducting GTT of 661 diabetic patients in single day at 13 different locations. The Company participated as main sponsor of World Ayurved Congress 2018 held in Ahmedabad. Apart from this, the Company inaugurated the opening of 200th Madhavbaug Clinic at Nanded, in Maharashtra.

In 2019, Madhavbaug introduced research based heart blockage management program. The Company achieved new registrations of over 90,000 patients and more than 27,000 stress tests were conducted and over 3,00,000 panchakarma procedures performed.

In 2020, the Company launched MIB Pulse Mobile Application for patient engagement.

In 2021, the Company inaugurated the opening of 250th Madhavbaug Clinic at Vashi. The Company's conducted Research trial on one year follow-up of diabetes patients treated by Madhavbaug was published in Journal of Association of Physicians of India. The Company achieved MIB Pulse Mobile Application over 1,00,000 downloads, which was developed by a third-party vendor. It calculated the risk of getting a heart attack by considering risk factors that a person has and also gave tips on how to reduce & manage the risk.

The Company has also launched online portal 'www.madhavbaugwellness.com' for new wellness products such as Madhav Shakti
Atta, apple cider vinegar, prosix dosa mix, nutriboom ghavan mix, digy smooth moong daliya, lentigrain idli mix, Insta health thalli peeth, power mix muthiya aata, diaphragm kadha, arj kadha, groundnut oil, amla lichi syrup, etc. and many more.

The Company made a public issue of 27,71,200 Equity Shares by raising funds aggregating to Rs. 20.22 Crore on 15 February, 2022.

In 2022-23, the Company incorporated F- Health Accelerators Private Limited as a Subsidiary Company. It further formed its Company in the name of 'Madhavbaug Health Food Supplements Trading Co. LLC' for awareness of Ayurveda at International Level in Dubai. In April 2023, the Company executed share purchase agreement with shareholders of Dynamic Remedies Private Limited and UV Ayurgen Pharma Private Limited to buy 100% equity share capital making them a wholly owned subsidiary of Company.

The Company has signed a Memorandum of Understanding (MOU) with Raja Ramdeo Anandilal Podar Central Ayurveda Research Institute (RRAPCARI) to undertake a research project entitled as 'Efficacy of Ayurvedic interventions (Hridyarnava Rasa and Harityakadi Yoga in 2023-24.

Parent organization Indian Private
NSE symbol MADHAVBAUG
Founded 1999
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Vaidya Sane Ayurved Laboratories Ltd?

Answer Field

Vaidya Sane Ayurved Laboratories Ltd share price is for NSE ₹ 199.95 & for BSE ₹ 0.00 as on May 22 2026 03:17 PM.

What is the Market Cap of Vaidya Sane Ayurved Laboratories Ltd Share?

Answer Field

The market cap of Vaidya Sane Ayurved Laboratories Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on May 22 2026 03:17 PM.

What is the 52 Week High and Low of Vaidya Sane Ayurved Laboratories Ltd?

Answer Field

The 52 Week High and Low of Vaidya Sane Ayurved Laboratories Ltd for NSE is ₹ 335.00 and ₹ 137.50 and for BSE is ₹ 0.00 and ₹ 0.00.

What is 1 year return for Vaidya Sane Ayurved Laboratories Ltd?

Answer Field

The 1 year returns on the stock has been 40.65%.

What is the P/E Ratio of Vaidya Sane Ayurved Laboratories Ltd Share?

Answer Field

As on May 22 2026 03:17 PM the price-to-earnings (PE) ratio for Vaidya Sane Ayurved Laboratories Ltd share is 41.24.

What is the PB ratio of Vaidya Sane Ayurved Laboratories Ltd Share?

Answer Field

As on May 22 2026 03:17 PM, the price-to-book (PB) ratio for Vaidya Sane Ayurved Laboratories Ltd share is 76.46.

How to Buy Vaidya Sane Ayurved Laboratories Ltd Share?

Answer Field

You can trade in Vaidya Sane Ayurved Laboratories Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Vaidya Sane Ayurved Laboratories Ltd Share on Bajaj Broking App?

Answer Field

To buy Vaidya Sane Ayurved Laboratories Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Vaidya Sane Ayurved Laboratories Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|